Protagonist Therapeutics, Inc.
NASDAQ:PTGXBiotechnology
+$1.72 today
- Market cap
- $8.30B
- Beta
- 1.83
- P/E (TTM)
- -64.2
- EPS (TTM)
- -$1.76
Volume 0.43M
Average 0.72M
PTGX Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Protagonist Therapeutics, Inc.NASDAQ: PTGX
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue growth accelerates
Q2 FY2026 revenue of $213.48M rose 3749.2% year over year, ahead of the +34.8% change in trailing-twelve-month revenue. Sequentially, it rose 278.7% from the prior quarter. Over 3 fiscal years it compounded at +20.1% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 9 analysts of $564.46M (+1126.7%) for the fiscal year ending Dec 2026, a step up from the -89.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $213.48M+278.7% QoQ
- Last fiscal yearDec 2025
- $46.02M-89.4% YoY
- LTMJun 2026
- $281.99M+34.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 46.02M USD
- Year-over-year change
- -89.4%
- 4-year CAGR
- +13.9%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.02M | -89.4% |
| FY2024 | 2024-12-31 | 434.43M | +624.1% |
| FY2023 | 2023-12-31 | 60M | +125.7% |
| FY2022 | 2022-12-31 | 26.58M | -2.8% |
| FY2021 | 2021-12-31 | 27.36M | — |
Revenue vs competitors
How PTGX compares with its peers on the latest reported figures
- PTGX's LTM Jun 2026 revenue of $281.99M is the highest of the 7 companies compared; the peer median is $7.73M.
- Its year-over-year change of +34.8% is the 2nd highest of 3, against a peer median of +27.4%.
- Over three fiscal years its annual growth of +20.1% compares with a peer median of +73.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $281.99M | +34.8% | +20.1% | |
| LTM Mar 2026 | $232.39M | +107.7% | +183.6% | |
| LTM Sep 2026 | $90.49M | — | — | |
| LTM Mar 2026 | $8.37M | -52.9% | -35.9% | |
| LTM Sep 2026 | $7.1M | — | — | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $0 | — | — |
| LTM Mar 2026 | $0 | — | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — |
| Peer median (excluding PTGX) | $7.73M | +27.4% | +73.8% | |
Competitors are the stored peer set for PTGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.36M | 26.58M | 60M | 434.43M | 46.02M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.23M |
| Gross Profit | 27.36M | 26.58M | 60M | 434.43M | 44.79M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 97.3% |
| Research & Development | 126.01M | 126.22M | 120.16M | 138.13M | 159.29M |
| Selling, General & Admin | 27.2M | 31.74M | 33.49M | 43.46M | 44.85M |
| Operating Expenses | 153.2M | 157.95M | 153.65M | 181.59M | 202.92M |
| Depreciation & Amortization | 2.78M | 3.37M | 3.31M | 2.96M | 1.28M |
| EBITDA | (122.78M) | (124.02M) | (75.64M) | 282.37M | (128.03M) |
| EBITDA Margin | -448.8% | -466.6% | -126.1% | 65.0% | -278.2% |
| Operating Income | (125.85M) | (131.37M) | (93.65M) | 252.84M | (158.13M) |
| Operating Margin | -460.0% | -494.2% | -156.1% | 58.2% | -343.6% |
| Interest Income | 443K | 4.06M | 14.9M | 26.32M | 28.79M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 294K | 3.98M | 14.7M | 26.57M | 28.82M |
| Income Before Tax | (125.55M) | (127.39M) | (78.96M) | 279.41M | (129.31M) |
| Pre-Tax Margin | -458.9% | -479.3% | -131.6% | 64.3% | -281.0% |
| Income Tax Expense | 0 | 0 | 0 | 4.22M | 838K |
| Net Income | (125.55M) | (127.39M) | (78.96M) | 275.19M | (130.15M) |
| Net Margin | -458.9% | -479.3% | -131.6% | 63.3% | -282.8% |
| EPS (Basic) | (2.65) | (2.52) | (1.39) | 4.47 | (2.05) |
| EPS (Diluted) | (2.65) | (2.52) | (1.39) | 4.23 | (2.05) |
| Weighted Avg Shares | 46.32M | 49.04M | 56.76M | 61.57M | 63.57M |
| Weighted Avg Shares (Diluted) | 46.32M | 49.04M | 56.76M | 65.08M | 63.57M |
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
Intrinsic Alpha fair value
Locked
Current Price
$127.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.